Not A Biosimilar: Mylan’s Insulin Glargine ‘Deemed’ A BLA With Long-Awaited US FDA Approval

 
• By Sue Sutter
the happiness of the person reaching the goal after a determined and patient struggle
After two complete response letters, Mylan and Biocon finally scored US FDA approval of their insulin glargine. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics